We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
hey busymum
nice to see your'e back
Thats an excellent post well done very informative looking to a brighter future GLA
*US/Canada (let’s not undersell the potential, imagine the cash flow from Canada alone).
The webinar was when Gabrielle mentioned launching StemprintER in Italy first followed by the UK/Europe secondly then US after that.
From memory, I haven’t seen GC or KS mention this on any videos yet.
just re-watched the videos with GC on the Tils website, the BOD are excited to have stem and bringing it to market, for all new/ and old investors take a look, I am sooooooo looking forward to the next 12 months
shiraz i was just trying to gauge that side of treatment and costs as dont know them, need to find the video of GC when he was talking about the start of Stem in Italy........any prognostic tool for diseases I am more than happy to be invested in, and the brucie bonus is i will be invested in 2 companies for the price of one, this company is on a mission to help mankind and i am happy to walk behind them.
Busy - long list of drugs and all very very expensive. There is a reason why pharma companies are the biggest in the world.
Busy- excellent post- this is why I was getting frustrated during the day. Some posters on here start panicking when the sp drops 5p. They dont realise that this is a potentially life changing investment for PI’s. Ive always felt tils will get taken out for $5 billion plus at some stage. This was before news of the brazil trial. This is a stock you lock away and come to a year later. Let the bod do their thing. This could be your pension. All major pharma are sniffing around for small biotechs with upside potential. Any success on our various trials and we will be first in queue for huge takeover. Dont forget 5 NDA’s. Even if covid trial fails we have another one starting q1 21. Its the best risk reward potential stock for me on aim and hence it forms 98% of my portfolio. Oh and chairman owns 33%. No brainer. All the best.
I know some here work in pharms, so what other drugs are used for breast cancer guys
Neratinib The basic NHS price for Nerlynx 40mg x 180 tablets (30 days treatment) is £4500
Therefore the cost of pertuzumab (excluding VAT) is estimated to be £4,790 for the initial dose and £2,395 for subsequent doses. The company has agreed a commercial access arrangement for pertuzumab with NHS England.
Trastuzumab The company estimates that the average cost of a course of treatment is £91,614, using the list price, and based on a 3-weekly dose of 3.6 mg/kg, a patient weight of 70.1 kg and an average length of treatment of 14.5 months.
These are 3 treatments that are used for breast cancer.
Now stem will be able to diagnose which treatment will work best for you.